Human Insulin Industry, October 2014 Market Reports from Top Publishers

You might be interested in: insulin, biosimilar, therapeutics, more »


 
1-10 of 14 reports for Human Insulin

Tonghua Dongbao Pharmaceutical Co., Ltd. (Symbol:600867) SWOT Analysis, Strategy, Revenues and Profits

Tonghua Dongbao Pharmaceutical Co., Ltd. (Symbol:600867) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Company, based in china. The company manufactures and sells pharmaceuticals. Its products include recombinant human insulin bulk drugs and injections, zhennaoning capsules, dongbao gantai tablets, as well ...

Adocia (ADOC) - Financial and Strategic SWOT Analysis Review

Adocia (ADOC) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Infection. It has completed phases i and ii studies of the formulation of fast-acting human insulin, phases i and ii studies of an ultra-fast acting insulin lispro and phase i/ii on a unique combination of insulin ...

Insulin Markets in China

Insulin Markets in China

  • $ 4 000
  • Industry report
  • September 2014
  • by Asia Market Information & Development Company

... And demandthe output and market share of animal insulin major producers china's human insulin production and demandthe output and market share of human insulin major producers china's insulin ...

Adocia (ADOC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Adocia (ADOC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • July 2014
  • by Global Data

... Infection. It has completed phases i and ii studies of the formulation of fast-acting human insulin, phases i and ii studies of an ultra-fast acting insulin lispro and phase i/ii on a unique combination of insulin ...

Biodel Inc. (BIOD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Biodel Inc. (BIOD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • May 2014
  • by Global Data

... Combines recombinant human insulin, or rhi, with its proprietary combination of excipients to increase the rate of absorption following injection when compared to other commercially available insulin ...

Bioton S.A. (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bioton S.A. (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • May 2014
  • by Global Data

... Products with focus on insulin treatment. The company's major products include recombinant human insulin for injections, oral hypoglycemic drugs containing live cultures of bacteria, antibiotics and eye ...

Biomm S.A. (BIOM4) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Biomm S.A. (BIOM4) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • April 2014
  • by Global Data

... Of human insulin and other recombinant proteins. Its technology is used in the production of therapeutic proteins, such as calcitonin, interferons and growth hormones. The company offers processes ...

Research and Forecast on China Insulin Market, 2014-2018

Research and Forecast on China Insulin Market, 2014-2018

  • $ 1 800
  • Industry report
  • April 2014
  • by Huidian Research

... And implementation of deepening medical and health system reform during the 12th five-year plan2.2.3 Comprehensive improved standards for insulin and recombinant human insulin in chinese pharmacopoeia 20102 ...

BIOTON S.A. (Symbol:BIO) SWOT Analysis, Strategy, Revenues and Profits

BIOTON S.A. (Symbol:BIO) SWOT Analysis, Strategy, Revenues and Profits

  • $ 125
  • Company report
  • February 2014
  • by Global Data

... Company that manufactures and distributes pharmaceutical products with focus on insulin treatment. The company's major products include recombinant human insulin for injections, oral hypoglycemic drugs ...

Global and China Insulin Industry Report, 2013-2017

Global and China Insulin Industry Report, 2013-2017

  • $ 1 900
  • Industry report
  • December 2013
  • by Research In China

... To technical barriers, china's insulin market is mainly occupied by novo nordisk, sanofi and eli lilly, of which, novo nordisk accounted for 60.3% In 2012. While in recombinant human insulin market segments ...

About 200 reports for Human Insulin

Download Unlimited Documents from Trusted Public Sources

Pathology Description in the US

  • Research Questions
  • September 2014
    10 pages
  • Insulin  

  • United States  

View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.